Insulin degludec has previously shown significantly better health-related quality of life outcomes compared with insulin glargine (as measured with the SF-36 instrument) in patients with Type 1 diabetes 17 and in patients with Type 2 diabetes on a basal–bolus regimen 16. The gene discussed is INS; the disease is type 2 diabetes mellitus.